AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca’s INTERSTELLAR study is a multi-national, observational research project aimed at evaluating the real-world effectiveness of Anifrolumab, a treatment for Systemic Lupus Erythematosus (SLE). The study’s primary goal is to provide evidence on the benefits of Anifrolumab when added to standard care, focusing on outcomes relevant to SLE treatment, including skin manifestations.
The intervention being tested is Anifrolumab, a monoclonal antibody designed to treat SLE by targeting specific immune pathways to reduce inflammation and disease activity.
The study is designed as a single-arm, observational cohort study with a prospective time perspective. It involves collecting data from patients across multiple countries who are receiving Anifrolumab as part of their routine clinical care.
The INTERSTELLAR study began on October 22, 2024, and is currently recruiting participants. The study’s last update was submitted on July 14, 2025. These dates are crucial as they mark the study’s progression and data collection phases.
This update may positively influence AstraZeneca’s stock performance by demonstrating the company’s commitment to advancing SLE treatment. The study’s findings could enhance investor confidence and position AstraZeneca favorably against competitors in the pharmaceutical industry.
The INTERSTELLAR study is ongoing, with further details available on the ClinicalTrials portal.